Toxicity evaluation of ConvitVax breast cancer immunotherapy

ConvitVax is a personalized vaccine for the treatment of breast cancer, composed of autologous tumor cells, bacillus Calmette-Guérin (BCG) and low concentrations of formalin. Previous pre-clinical studies show that this therapy induces a potent activation of the immune system and achieves an effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Duarte C., María A., Carballo O., Jeismar M., De Gouveia, Yetsenia M., García, Angie, Ruiz, Diana, Gledhill, Teresa, González-Marcano, Eglys, Convit, Ana F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209199/
https://www.ncbi.nlm.nih.gov/pubmed/34135375
http://dx.doi.org/10.1038/s41598-021-91995-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209199/
https://www.ncbi.nlm.nih.gov/pubmed/34135375
http://dx.doi.org/10.1038/s41598-021-91995-6

Ejemplares similares